Physician profile
Seth E Rosenzweig
NPI 1184691511
$2,759.39
in general payments reported to CMS, 2019-2025
27 companies · $72.29 in 2025
The $72.29 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $801 · 2020: $397 · 2021: $696 · 2022: $394 · 2023: $25.86 · 2024: $373 · 2025: $72.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $432 · Education: $39.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $431.52 |
| Education | $39.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $674.89 | 2019-2023 | Rinvoq |
| Janssen Biotech, INC. | $363.45 | 2019-2025 | Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $269.65 | 2019-2024 | Xifaxan |
| Gilead Sciences, INC. | $171.73 | 2019-2021 | |
| Celgene Corporation | $159.72 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $129.63 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2024 | Zeposia |
| Ucb, INC. | $113.15 | 2019-2020 | |
| Pfizer INC. | $107.72 | 2019-2021 | |
| Boston Scientific Corporation | $92.77 | 2020 | |
| Redhill Biopharma INC. | $71.57 | 2020-2021 | |
| Biofire Diagnostics, LLC | $58.97 | 2019 | |
| Madrigal Pharmaceuticals | $58.28 | 2024 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $50.19 | 2021-2022 | |
| Braintree Laboratories, INC. | $34.76 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $33.46 | 2019 | |
| Shionogi INC | $32.90 | 2019 | |
| Ferring Pharmaceuticals INC. | $26.38 | 2021-2023 | Rebyota |
| Ironwood Pharmaceuticals, INC | $25.77 | 2020 | |
| Daiichi Sankyo INC. | $25.69 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $25.15 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $21.83 | 2022 | |
| Qol Medical, LLC | $20.82 | 2022 | |
| Olympus America INC. | $19.44 | 2024 | Endoclot Phs |
| Novo Nordisk INC | $19.34 | 2025 | Wegovy |
| Medtronic, INC. | $15.44 | 2021 | |
| Merck Sharp & Dohme LLC | $11.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Rosenzweig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.